Monoclonal antibodies targeting plasma cells as novel therapeutic agents and diagnostic tools

靶向浆细胞的单克隆抗体作为新型治疗剂和诊断工具

• 批准号: nhmrc : 575575
• 负责人: Prof David Tarlinton
• 金额: $ 13.29万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/monoclonal-antibodies-targeting-diagnostic-tools/100016
• 关键词: Monoclonal; antibodies; targeting; plasma; cells

We have a new tool to identify a very rare immune cell type. This cell makes antibodies, powerful and exquisitely specific proteins that fight infection. In health, antibody-producing cells are beneficial, but in disease (rheumatoid arthritis, lupus and myeloma), these cells cause disease or death. Antibody-producing cells are long-lived. We have no means to specifically deplete them. We are developing reagents to identify and deplete antibody-producing cells to use as novel therapeutic agents.

我们有一种新的工具来识别一种非常罕见的免疫细胞类型。这种细胞产生抗体，一种强大而特异的蛋白质，可以抵抗感染。在健康状况下，产生抗体的细胞是有益的，但在疾病（类风湿性关节炎，狼疮和骨髓瘤）中，这些细胞会导致疾病或死亡。产生抗体的细胞寿命很长。我们没有办法专门消耗它们。我们正在开发试剂来识别和耗尽抗体产生细胞，以用作新型治疗剂。